Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05), $0.08 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $10.11 million versus the consensus estimate of $21.6 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.